| abstract |
Described herein are HIV vaccines based on first generation adenovirus vectors and related recombinant adenoviruses that exhibit enhanced stability and growth characteristics and greater cellular immunity. These adenovirus vectors are based on a variety of adenoviruses containing HIV-1 gag, HIV-1 pol and / or HIV-1 nef polynucleotide pharmaceuticals and biologically relevant modifications thereof by cell culture. Used to make and produce HIV-1 vaccines. These adenovirus vaccines, when introduced directly into live vertebrate tissue, preferably a mammalian host (e.g., a human, or a non-human mammal of commercial or veterinary importance) are useful for HIV1-Gag, Pol. And / or expresses a Nef protein or a biologically modified form thereof to induce a cellular immune response that specifically recognizes HIV-1. Exemplary polynucleotides of the invention include HIV-1 @ Gag, encoded codon optimized HIV-1 @ Pol, derivatives of optimized HIV-1 @ Pol (HIV-1 @ Pol protease, reverse transcriptase, RNase H and Derivatives of HIV-1 さ れ Nef and optimized HIV-1 Nef (including constructs in which integrase activity has been inactivated), nef suddenly affect wild-type properties of Nef such as downregulation and myristylation of host CD4 (Including mutants). The adenovirus vaccines of the present invention, when administered alone or in a combination manner, provide a prophylactic benefit to previously uninfected individuals and / or reduce the viral load level in infected individuals and reduce HIV load. Prolonging the asymptomatic phase of an infection would provide a therapeutic effect. |